Condition: Non-small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC) · Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: Revolution Medicines, Inc.
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
This description comes directly from the study's public registry record.
Revolution Medicines, Inc. · 1-844-2-REVMED · medinfo@RevMed.com
Always discuss trial participation with your own doctor first.
| University of California, Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| Smilow Cancer Hospital (Yale University) | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Lee Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| NYU Langone | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Duke Cancer Center | Durham, North Carolina, United States | Recruiting |
| Carolina BioOncology Institute | Huntersville, North Carolina, United States | Recruiting |
| The Christ Hospital | Cincinnati, Ohio, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06040541